| 70-gene signature as an aid to treatment decisions in early-stage breast cancer F Cardoso, LJ van’t Veer, J Bogaerts, L Slaets, G Viale, S Delaloge, ... New England Journal of Medicine 375 (8), 717-729, 2016 | 1982 | 2016 |
| Association analysis identifies 65 new breast cancer risk loci K Michailidou, S Lindström, J Dennis, J Beesley, S Hui, S Kar, A Lemaçon, ... Nature 551 (7678), 92-94, 2017 | 1465 | 2017 |
| Polygenic risk scores for prediction of breast cancer and breast cancer subtypes N Mavaddat, K Michailidou, J Dennis, M Lush, L Fachal, A Lee, JP Tyrer, ... The American Journal of Human Genetics 104 (1), 21-34, 2019 | 1017 | 2019 |
| Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data FC Bidard, DJ Peeters, T Fehm, F Nolé, R Gisbert-Criado, D Mavroudis, ... The lancet oncology 15 (4), 406-414, 2014 | 964 | 2014 |
| 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3) F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ... The Breast 31, 244-259, 2017 | 924 | 2017 |
| Breast cancer risk genes—association analysis in more than 113,000 women Breast Cancer Association Consortium New England Journal of Medicine 384 (5), 428-439, 2021 | 757 | 2021 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 684 | 2017 |
| Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group E Zucca, A Conconi, TI Mughal, AH Sarris, JF Seymour, U Vitolo, R Klasa, ... Journal of Clinical Oncology 21 (1), 20-27, 2003 | 584 | 2003 |
| FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal … J Souglakos, N Androulakis, K Syrigos, A Polyzos, N Ziras, ... British journal of cancer 94 (6), 798-805, 2006 | 533 | 2006 |
| Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 M Kaufmann, G Von Minckwitz, HD Bear, A Buzdar, P McGale, H Bonnefoi, ... Annals of Oncology 18 (12), 1927-1934, 2007 | 491 | 2007 |
| 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial X Pivot, G Romieu, M Debled, JY Pierga, P Kerbrat, T Bachelot, ... The lancet oncology 14 (8), 741-748, 2013 | 464 | 2013 |
| Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients G Kallergi, MA Papadaki, E Politaki, D Mavroudis, V Georgoulias, ... Breast Cancer Research 13, 1-11, 2011 | 453 | 2011 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 436 | 2020 |
| Molecular detection of cytokeratin-19–positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance A Stathopoulou, I Vlachonikolis, D Mavroudis, M Perraki, C Kouroussis, ... Journal of Clinical Oncology 20 (16), 3404-3412, 2002 | 429 | 2002 |
| Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells J Molldrem, S Dermime, K Parker, YZ Jiang, D Mavroudis, N Hensel, ... | 427 | 1996 |
| A HUPO test sample study reveals common problems in mass spectrometry–based proteomics AW Bell, EW Deutsch, CE Au, RE Kearney, R Beavis, S Sechi, T Nilsson, ... Nature methods 6 (6), 423-430, 2009 | 410 | 2009 |
| Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer RL Milne, KB Kuchenbaecker, K Michailidou, J Beesley, S Kar, ... Nature genetics 49 (12), 1767-1778, 2017 | 406 | 2017 |
| Antithymocyte globulin for patients with myelodysplastic syndrome JJ Molldrem, M Caples, D Mavroudis, M Plante, NS Young, AJ Barrett British journal of haematology 99 (3), 699-705, 1997 | 371 | 1997 |
| Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer PA Theodoropoulos, H Polioudaki, S Agelaki, G Kallergi, Z Saridaki, ... Cancer letters 288 (1), 99-106, 2010 | 370 | 2010 |
| Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer … R Gray, R Bradley, J Braybrooke, Z Liu, R Peto, L Davies, D Dodwell, ... The lancet 393 (10179), 1440-1452, 2019 | 361 | 2019 |
